Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTTI with Immunosuppression for Complete DiGeorge Anomaly
NCT00579527Phase 2Completed
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2005
- Primary completion
- Dec 2011
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rethymic in Velocardiofacial syndrome (VCFS), sponsored by Sumitomo Pharma. Primary endpoint: Survival at 1 Year Post-CTTI. Started Dec 2005; status: completed.
02
Drugs
Rethymic
03
Conditions
Velocardiofacial syndrome (VCFS)
Beyond the preview
Go deeper on NCT00579527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00579527.